News/MT Newswires/ImmunoGen Says FDA Approves Biologics License Application of Mirv…ImmunoGen Says FDA Approves Biologics License Application of Mirvetuximab Soravtansine With Priority ReviewMay 23, 202210:42 UTCIIMGN